MedTrace Logo

Expanded Access Protocol for an Intermediate Size Population - RAVICTI for Byler Disease

NCT02094222 · Status: NO_LONGER_AVAILABLE · Type: EXPANDED_ACCESS

Last updated 2019-02-18

No results posted yet for this study

Summary

Byler Disease is the result of a homozygous missense (G308V) mutation in the ATP8B1 gene. The disease is typically manifest in the first year of life on the basis of complications of cholestasis; common presentations include jaundice, poor growth, bleeding related to vitamin K deficiency, and/or weak bones related to vitamin D deficiency. Early management of Byler Disease is directed at nutritional issues which tend to be responsive to medical intervention, unlike the pruritus/scratching which remains a devastating problem. Progressive liver disease develops in Byler Disease and can lead to cirrhosis and end-stage liver disease. This is an open label expanded access protocol of RAVICTI in children with Byler Disease. The primary hypothesis is that the administration of RAVICTI in these children is feasible, well tolerated and safe. It is also hypothesized that RAVICTI treatment leads to an improvement in biochemical markers of liver disease and it may ameliorates or prevents the development of scratching behavior as a manifestation of pruritus attributed to the liver disease.

Conditions

  • Byler Disease

Interventions

DRUG

RAVICTI

open label expanded access protocol of titrated dosing regimen of RAVICTI for up to 60 weeks

Sponsors & Collaborators

  • Robert Squires, Jr.

    lead OTHER

Principal Investigators

  • Robert H Squires, MD · University of Pittsburgh

Eligibility

Min Age
130 Days
Max Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT02094222 on ClinicalTrials.gov